Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 766

1.

Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database.

Zapata DF, Howard LE, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Freedland SJ.

Int J Urol. 2015 Apr 14. doi: 10.1111/iju.12773. [Epub ahead of print]

PMID:
25872110
2.

JNCI and cancer prevention.

Dunn BK, Ghosh S, Kramer BS.

J Natl Cancer Inst. 2015 Feb 24;107(3). pii: djv021. doi: 10.1093/jnci/djv021. Print 2015 Mar.

PMID:
25713150
3.

Survey of clinical and pathological characteristics and outcomes of patients with prostate cancer.

Alizadeh M, Alizadeh S.

Glob J Health Sci. 2014 Sep 18;6(7 Spec No):49-57. doi: 10.5539/gjhs.v6n7p49.

4.

Prevention and early detection of prostate cancer.

Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, La Vecchia C, Lilja H, Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner S, Rittenhouse H, Schalken J, Schmid HP, Schmitz-Dräger BJ, Schröder FH, Stenzl A, Tombal B, Wilt TJ, Wolk A.

Lancet Oncol. 2014 Oct;15(11):e484-92. doi: 10.1016/S1470-2045(14)70211-6. Review.

PMID:
25281467
6.

Cigarette smoking and variations in systemic immune and inflammation markers.

Shiels MS, Katki HA, Freedman ND, Purdue MP, Wentzensen N, Trabert B, Kitahara CM, Furr M, Li Y, Kemp TJ, Goedert JJ, Chang CM, Engels EA, Caporaso NE, Pinto LA, Hildesheim A, Chaturvedi AK.

J Natl Cancer Inst. 2014 Oct 1;106(11). pii: dju294. doi: 10.1093/jnci/dju294. Print 2014 Nov.

PMID:
25274579
7.

[Molecular classification of urogenital cancers].

Tímár J.

Magy Onkol. 2014 Sep;58(3):157-60. Epub 2014 Aug 2. Review. Hungarian.

8.

Incidence of second malignancies in prostate cancer patients treated with low-dose-rate brachytherapy and radical prostatectomy.

Hamilton SN, Tyldesley S, Hamm J, Jiang WN, Keyes M, Pickles T, Lapointe V, Kahnamelli A, McKenzie M, Miller S, Morris WJ.

Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):934-41. doi: 10.1016/j.ijrobp.2014.07.032. Epub 2014 Sep 17.

PMID:
25240272
9.

Appraisal of diagnostic ability of UCA1 as a biomarker of carcinoma of the urinary bladder.

Srivastava AK, Singh PK, Rath SK, Dalela D, Goel MM, Bhatt ML.

Tumour Biol. 2014 Nov;35(11):11435-42. doi: 10.1007/s13277-014-2474-z. Epub 2014 Aug 15.

PMID:
25123267
10.

Development of clinical models for predicting erectile function after localized prostate cancer treatment.

Haskins AE, Han PK, Lucas FL, Bristol I, Hansen M.

Int J Urol. 2014 Dec;21(12):1227-33. doi: 10.1111/iju.12566. Epub 2014 Jul 23.

PMID:
25056284
11.

Serum uric acid levels and cancer mortality risk among males in a large general population-based cohort study.

Taghizadeh N, Vonk JM, Boezen HM.

Cancer Causes Control. 2014 Aug;25(8):1075-80. doi: 10.1007/s10552-014-0408-0. Epub 2014 Jun 7.

12.

Bladder neck contractures and the prostate cancer survivor.

Song JS, Eswara JR, Brandes SB.

Curr Opin Urol. 2014 Jul;24(4):389-94. doi: 10.1097/MOU.0000000000000065. Review.

PMID:
24901516
13.

Tobacco smoking patterns and differential food effects on prostate and breast cancers among smokers and nonsmokers in Córdoba, Argentina.

Román MD, Niclis C, Tumas N, Díaz Mdel P, Osella AR, Muñoz SE.

Eur J Cancer Prev. 2014 Jul;23(4):310-8. doi: 10.1097/CEJ.0000000000000044.

PMID:
24871563
14.

Diabetes mellitus and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition.

Tsilidis KK, Allen NE, Appleby PN, Rohrmann S, Nöthlings U, Arriola L, Gunter MJ, Chajes V, Rinaldi S, Romieu I, Murphy N, Riboli E, Tzoulaki I, Kaaks R, Lukanova A, Boeing H, Pischon T, Dahm CC, Overvad K, Quirós JR, Fonseca-Nunes A, Molina-Montes E, Gavrila Chervase D, Ardanaz E, Khaw KT, Wareham NJ, Roswall N, Tjønneland A, Lagiou P, Trichopoulos D, Trichopoulou A, Palli D, Pala V, Tumino R, Vineis P, Bueno-de-Mesquita HB, Malm J, Orho-Melander M, Johansson M, Stattin P, Travis RC, Key TJ.

Int J Cancer. 2015 Jan 15;136(2):372-81. doi: 10.1002/ijc.28989. Epub 2014 Jun 3.

PMID:
24862312
15.

Elevated HERV-K mRNA expression in PBMC is associated with a prostate cancer diagnosis particularly in older men and smokers.

Wallace TA, Downey RF, Seufert CJ, Schetter A, Dorsey TH, Johnson CA, Goldman R, Loffredo CA, Yan P, Sullivan FJ, Giles FJ, Wang-Johanning F, Ambs S, Glynn SA.

Carcinogenesis. 2014 Sep;35(9):2074-83. doi: 10.1093/carcin/bgu114. Epub 2014 May 23.

PMID:
24858205
16.

Prostate cancer incidence and prostate-specific antigen testing among HIV-positive and HIV-negative men.

Marcus JL, Chao CR, Leyden WA, Xu L, Klein DB, Horberg MA, Towner WJ, Quesenberry CP Jr, Abrams DI, Van Den Eeden SK, Silverberg MJ.

J Acquir Immune Defic Syndr. 2014 Aug 15;66(5):495-502. doi: 10.1097/QAI.0000000000000202.

PMID:
24820107
17.

Late toxicity and quality of life after definitive treatment of prostate cancer: redefining optimal rectal sparing constraints for intensity-modulated radiation therapy.

Chennupati SK, Pelizzari CA, Kunnavakkam R, Liauw SL.

Cancer Med. 2014 Aug;3(4):954-61. doi: 10.1002/cam4.261. Epub 2014 May 6.

18.

Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: A population-based, propensity score analysis.

Antwi S, Everson TM.

Cancer Epidemiol. 2014 Aug;38(4):435-41. doi: 10.1016/j.canep.2014.04.002. Epub 2014 May 5.

PMID:
24802851
19.

15-year cause specific and all-cause survival following brachytherapy for prostate cancer: negative impact of long-term hormonal therapy.

Stone NN, Stock RG.

J Urol. 2014 Sep;192(3):754-9. doi: 10.1016/j.juro.2014.03.094. Epub 2014 Mar 31.

PMID:
24698961
20.

What should we tell prostate cancer patients about (secondary) prevention?

Chan JM, Van Blarigan EL, Kenfield SA.

Curr Opin Urol. 2014 May;24(3):318-23. doi: 10.1097/MOU.0000000000000049. Review.

PMID:
24625429
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk